Global Information
회사소개 | 문의 | 비교리스트

세계의 핵의학 시장 : 예측과 기회(-2025년)

Global Nuclear Medicine Market By Therapy, By Type, By Application, By Therapeutics, By Route of Administration, By End-User, By Region, Forecast & Opportunities, 2025

리서치사 TechSci Research
발행일 2020년 05월 상품 코드 934739
페이지 정보 영문 110 Pages
가격
US $ 4,450 ₩ 5,077,000 Unprintable PDF and Excel (Single User License)
US $ 5,450 ₩ 6,217,000 PDF and Excel (Multi-User License)
US $ 9,450 ₩ 10,781,000 PDF and Excel (Custom Research License)

TechSci Research 보고서는 10% Customization 서비스가 포함되어 있습니다. 보고서에 포함돼 있지 않은 리서치 데이터와 시장 동향을 추가적으로 요청할 수 있습니다. 자세한 사항은 문의하여 주시기 바랍니다.



세계의 핵의학 시장 : 예측과 기회(-2025년) Global Nuclear Medicine Market By Therapy, By Type, By Application, By Therapeutics, By Route of Administration, By End-User, By Region, Forecast & Opportunities, 2025
발행일 : 2020년 05월 페이지 정보 : 영문 110 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 핵의학(Nuclear Medicine) 시장은 암 등 질환의 발생률과 유병률 증가, Mo-99의 수급 격차를 감소하기 위한 구상, 다양한 치료를 위한 방사선 요법의 연구개발 활동 증가에 의해 2025년까지 급속도로 성장할 것으로 예측되고 있습니다. 또한 핵의학은 분자 이미징에서 폭넓게 사용되고 있습니다. 분자 이미징은 질환의 발증 또는 진행을 결정하는 특정 분자 프로세스의 바이오마커로서 분자를 사용하는 방법입니다.

세계의 핵의학 시장을 치료별, 유형별, 용도별, 치료학별, 투여 경로별, 최종사용자별, 지역별로 조사했으며, 시장 규모 및 시장 점유율 예측, 촉진요인과 과제, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 제품 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 핵의학 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 치료별(방사성 요오드, 방사성 항체, 방사성 인, 기타)
    • 유형별(SPECT(Single photo emission computed tomography), PET(양전자 방출 단층촬영), 알파 이미터, 베타 이미터, 근접 조사 요법)
    • 용도별(순환기, 호흡기, 정형외과, 신경학, 종양학, 비뇨기과)
    • 치료학별(알파 입자 이미터, 베타 입자 이미터, 오거 전자 이미터)
    • 투여 경로별(경구, 점적, 경비)
    • 최종사용자별(병원, 진단 센터, 기타)
    • 기업별(2019년)
    • 지역별
  • 시장의 매력 지수

제6장 아시아태평양의 핵의학 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 치료별
    • 유형별
    • 용도별
    • 치료학별
    • 투여 경로별
    • 최종사용자별
    • 국가별
  • 시장의 매력 지수
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 싱가포르
    • 호주

제7장 유럽의 핵의학 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 치료별
    • 유형별
    • 용도별
    • 치료학별
    • 투여 경로별
    • 최종사용자별
    • 국가별
  • 시장의 매력 지수
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 러시아
    • 스페인

제8장 북미의 핵의학 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 치료별
    • 유형별
    • 용도별
    • 치료학별
    • 투여 경로별
    • 최종사용자별
    • 국가별
  • 시장의 매력 지수
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제9장 남미의 핵의학 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 치료별
    • 유형별
    • 용도별
    • 치료학별
    • 투여 경로별
    • 최종사용자별
    • 국가별
  • 시장의 매력 지수
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동·아프리카의 핵의학 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 치료별
    • 유형별
    • 용도별
    • 치료학별
    • 투여 경로별
    • 최종사용자별
    • 국가별
  • 시장의 매력 지수
  • 중동·아프리카 지역 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • UAE

제11장 시장 역학

  • 촉진요인
  • 과제

제12장 시장 동향과 발전

제13장 경쟁 구도

  • 경쟁 전망
  • 주요 기업 개요
    • Cardinal Health
    • Curium
    • Lantheus
    • Bracco
    • Advanced Accelerator Applications
    • NTP Radioisotopes
    • Eckert & Ziegler
    • Jubilant DraxImage
    • GE Healthcare
    • Siemens Healthineers
    • Rotem Industries
    • Eczacibasi-Monrol
    • IBA Group
    • Ire-Elit
    • Lucerno Dynamics
    • Positron Corporation
    • NorthStar Medical Radioisotopes
    • Pharmalucence
    • Norgine
    • Roche

제14장 전략적 권장사항

제15장 회사와 면책사항 소개

KSA 20.05.18

Global nuclear medicine market is estimated to grow at an impressive rate during the forecast period owing to increasing incidence and prevalence of diseases like cancer, initiatives to reduce the demand and supply gap of Mo-99 and increasing research and development activities in radiotherapy to treat various diseases. Furthermore, nuclear medicines are extensively being used in molecular imaging, which is a technique involving molecules as biomarkers for specific molecular processes that determines the onset or progress of a disease.

Nuclear medicines are convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Due to this major factor, chemotherapy methods are being replaced by radiopharmaceuticals or nuclear medicines for cancer treatment. They are also used in applications such as lymphoma and bone metastasis. Some of the nuclear medicines used in diagnostic procedures are F-18, Tc-99, Ga-67, and I-123 while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures. These factors are anticipated to drive global nuclear medicine market until 2025.

Apart from above mentioned growth factors, the global nuclear medicine market also faces some restrains. Short half-life of nuclear medicines or radiopharmaceuticals reduces their potential adoption. Other restraining factors include supply shortages, logistical difficulties, and limited number of trained medical personnel.

The global nuclear medicine market is segmented based on therapy, type, application, therapeutics, route of administration, end-user and region. Based on application, the global nuclear medicine market is segmented into cardiology, respiratory, orthopaedics, neurology, oncology and urology. Among them, the oncology segment accounts for the major market share due to increasing prevalence of cancer worldwide. Based on type, the nuclear medicine market is segmented into SPECT, PET, alpha-emitters, beta-emitters and brachytherapy. The SPECT segment accounts for the largest market share and is expected to hold its dominance in the coming years owing to low cost and wide usage in different applications.

Major players operating in the global nuclear medicine market include Cardinal Health, Curium, Lantheus, Bracco, Advanced Accelerator Applications, NTP Radioisotopes, Eckert & Ziegler, Jubilant DraxImage, GE Healthcare, Siemens Healthineers, Rotem Industries, Eczacibasi-Monrol, IBA Group, Ire-Elit, Lucerno Dynamics, Positron Corporation, NorthStar Medical Radioisotopes, Pharmalucence, Norgine, Roche and others. Key market players are implementing activities like product developments, business expansion, and collaborative development to maintain significant share in the market for nuclear medicine.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study

  • To analyze and forecast the market size of global nuclear medicine market.
  • To classify and forecast global nuclear medicine market based on therapy, type, application, therapeutics, route of administration, end-user, company and regional distribution.
  • To identify drivers and challenges for global nuclear medicine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global nuclear medicine market.
  • To conduct pricing analysis for global nuclear medicine market.
  • To identify and analyze the profile of leading players operating in global nuclear medicine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global nuclear medicine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Nuclear medicine manufacturer, suppliers, distributors and other stakeholders
  • Hospitals & Clinics
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to nuclear medicine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global nuclear medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Therapy:

Radioactive Iodine

Radioactive Antibodies

Radioactive Phosphorus

Others

  • Market, By Type:

SPECT (Single Photo Emission Computed Tomography)

PET (Positron Emission Tomography)

Alpha-emitters

Beta-emitters

Brachytherapy

  • Market, By Application:

Cardiology

Respiratory

Orthopaedics

Neurology

Oncology

Urology

  • Market, By Therapeutics:

Alpha Particle Emitters

Beta Particle Emitters

Auger Electron Emitters

  • Market, By Route of Administration:

Oral

Intravenous

Nasal

  • Market, By End-User:

Hospitals

Diagnostic Centers

Others

  • Market, By Region:

Asia-Pacific

Europe

North America

South America

Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global nuclear medicine market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Nuclear Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Radioactive Iodine, Radioactive Antibodies, Radioactive Phosphorus, Others
    • 5.2.2. By Type (SPECT (Single photo emission computed tomography), PET (Positron emission tomography), Alpha-emitters, Beta-emitters, Brachytherapy)
    • 5.2.3. By Application (Cardiology, Respiratory, Orthopaedics, Neurology, Oncology, Urology)
    • 5.2.4. By Therapeutics (Alpha Particle Emitters, Beta Particle Emitters, Auger Electron Emitters)
    • 5.2.5. By Route of Administration (Oral, Intravenous, Nasal)
    • 5.2.6. By End-User (Hospitals, Diagnostic centers, Others)
    • 5.2.7. By Company (2019)
    • 5.2.8. By Region
  • 5.3. Market Attractiveness Index

6. Asia-Pacific Nuclear Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Type
    • 6.2.3. By Application
    • 6.2.4. By Therapeutics
    • 6.2.5. By Route of Administration
    • 6.2.6. By End-User
    • 6.2.7. By Country
  • 6.3. Market Attractiveness Index
  • 6.4. Asia-Pacific: Country Analysis
    • 6.4.1. China Nuclear Medicine Market Outlook
      • 6.4.1.1. Market Size & Forecast
        • 6.4.1.1.1. By Value
      • 6.4.1.2. Market Share & Forecast
        • 6.4.1.2.1. By Therapy
        • 6.4.1.2.2. By Type
        • 6.4.1.2.3. By Application
        • 6.4.1.2.4. By Therapeutics
        • 6.4.1.2.5. By Route of Administration
        • 6.4.1.2.6. By End-User
    • 6.4.2. India Nuclear Medicine Market Outlook
      • 6.4.2.1. Market Size & Forecast
        • 6.4.2.1.1. By Value
      • 6.4.2.2. Market Share & Forecast
        • 6.4.2.2.1. By Therapy
        • 6.4.2.2.2. By Type
        • 6.4.2.2.3. By Application
        • 6.4.2.2.4. By Therapeutics
        • 6.4.2.2.5. By Route of Administration
        • 6.4.2.2.6. By End-User
    • 6.4.3. Japan Nuclear Medicine Market Outlook
      • 6.4.3.1. Market Size & Forecast
        • 6.4.3.1.1. By Value
      • 6.4.3.2. Market Share & Forecast
        • 6.4.3.2.1. By Therapy
        • 6.4.3.2.2. By Type
        • 6.4.3.2.3. By Application
        • 6.4.3.2.4. By Therapeutics
        • 6.4.3.2.5. By Route of Administration
        • 6.4.3.2.6. By End-User
    • 6.4.4. South Korea Nuclear Medicine Market Outlook
      • 6.4.4.1. Market Size & Forecast
        • 6.4.4.1.1. By Value
      • 6.4.4.2. Market Share & Forecast
        • 6.4.4.2.1. By Therapy
        • 6.4.4.2.2. By Type
        • 6.4.4.2.3. By Application
        • 6.4.4.2.4. By Therapeutics
        • 6.4.4.2.5. By Route of Administration
        • 6.4.4.2.6. By End-User
    • 6.4.5. Singapore Nuclear Medicine Market Outlook
      • 6.4.5.1. Market Size & Forecast
        • 6.4.5.1.1. By Value
      • 6.4.5.2. Market Share & Forecast
        • 6.4.5.2.1. By Therapy
        • 6.4.5.2.2. By Type
        • 6.4.5.2.3. By Application
        • 6.4.5.2.4. By Therapeutics
        • 6.4.5.2.5. By Route of Administration
        • 6.4.5.2.6. By End-User
    • 6.4.6. Australia Nuclear Medicine Market Outlook
      • 6.4.6.1. Market Size & Forecast
        • 6.4.6.1.1. By Value
      • 6.4.6.2. Market Share & Forecast
        • 6.4.6.2.1. By Therapy
        • 6.4.6.2.2. By Type
        • 6.4.6.2.3. By Application
        • 6.4.6.2.4. By Therapeutics
        • 6.4.6.2.5. By Route of Administration
        • 6.4.6.2.6. By End-User

7. Europe Nuclear Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Type
    • 7.2.3. By Application
    • 7.2.4. By Therapeutics
    • 7.2.5. By Route of Administration
    • 7.2.6. By End-User
    • 7.2.7. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. Europe: Country Analysis
    • 7.4.1. France Nuclear Medicine Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Therapy
        • 7.4.1.2.2. By Type
        • 7.4.1.2.3. By Application
        • 7.4.1.2.4. By Therapeutics
        • 7.4.1.2.5. By Route of Administration
        • 7.4.1.2.6. By End-User
    • 7.4.2. Germany Nuclear Medicine Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Therapy
        • 7.4.2.2.2. By Type
        • 7.4.2.2.3. By Application
        • 7.4.2.2.4. By Therapeutics
        • 7.4.2.2.5. By Route of Administration
        • 7.4.2.2.6. By End-User
    • 7.4.3. United Kingdom Nuclear Medicine Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Therapy
        • 7.4.3.2.2. By Type
        • 7.4.3.2.3. By Application
        • 7.4.3.2.4. By Therapeutics
        • 7.4.3.2.5. By Route of Administration
        • 7.4.3.2.6. By End-User
    • 7.4.4. Italy Nuclear Medicine Market Outlook
      • 7.4.4.1. Market Size & Forecast
        • 7.4.4.1.1. By Value
      • 7.4.4.2. Market Share & Forecast
        • 7.4.4.2.1. By Therapy
        • 7.4.4.2.2. By Type
        • 7.4.4.2.3. By Application
        • 7.4.4.2.4. By Therapeutics
        • 7.4.4.2.5. By Route of Administration
        • 7.4.4.2.6. By End-User
    • 7.4.5. Russia Nuclear Medicine Market Outlook
      • 7.4.5.1. Market Size & Forecast
        • 7.4.5.1.1. By Value
      • 7.4.5.2. Market Share & Forecast
        • 7.4.5.2.1. By Therapy
        • 7.4.5.2.2. By Type
        • 7.4.5.2.3. By Application
        • 7.4.5.2.4. By Therapeutics
        • 7.4.5.2.5. By Route of Administration
        • 7.4.5.2.6. By End-User
    • 7.4.6. Spain Nuclear Medicine Market Outlook
      • 7.4.6.1. Market Size & Forecast
        • 7.4.6.1.1. By Value
      • 7.4.6.2. Market Share & Forecast
        • 7.4.6.2.1. By Therapy
        • 7.4.6.2.2. By Type
        • 7.4.6.2.3. By Application
        • 7.4.6.2.4. By Therapeutics
        • 7.4.6.2.5. By Route of Administration
        • 7.4.6.2.6. By End-User

8. North America Nuclear Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Type
    • 8.2.3. By Application
    • 8.2.4. By Therapeutics
    • 8.2.5. By Route of Administration
    • 8.2.6. By End-User
    • 8.2.7. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Nuclear Medicine Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Therapy
        • 8.4.1.2.2. By Type
        • 8.4.1.2.3. By Application
        • 8.4.1.2.4. By Therapeutics
        • 8.4.1.2.5. By Route of Administration
        • 8.4.1.2.6. By End-User
    • 8.4.2. Mexico Nuclear Medicine Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Therapy
        • 8.4.2.2.2. By Type
        • 8.4.2.2.3. By Application
        • 8.4.2.2.4. By Therapeutics
        • 8.4.2.2.5. By Route of Administration
        • 8.4.2.2.6. By End-User
    • 8.4.3. Canada Nuclear Medicine Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Therapy
        • 8.4.3.2.2. By Type
        • 8.4.3.2.3. By Application
        • 8.4.3.2.4. By Therapeutics
        • 8.4.3.2.5. By Route of Administration
        • 8.4.3.2.6. By End-User

9. South America Nuclear Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Type
    • 9.2.3. By Application
    • 9.2.4. By Therapeutics
    • 9.2.5. By Route of Administration
    • 9.2.6. By End-User
    • 9.2.7. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. South America: Country Analysis
    • 9.4.1. Brazil Nuclear Medicine Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Therapy
        • 9.4.1.2.2. By Type
        • 9.4.1.2.3. By Application
        • 9.4.1.2.4. By Therapeutics
        • 9.4.1.2.5. By Route of Administration
        • 9.4.1.2.6. By End-User
    • 9.4.2. Argentina Nuclear Medicine Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Therapy
        • 9.4.2.2.2. By Type
        • 9.4.2.2.3. By Application
        • 9.4.2.2.4. By Therapeutics
        • 9.4.2.2.5. By Route of Administration
        • 9.4.2.2.6. By End-User
    • 9.4.3. Colombia Nuclear Medicine Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Therapy
        • 9.4.3.2.2. By Type
        • 9.4.3.2.3. By Application
        • 9.4.3.2.4. By Therapeutics
        • 9.4.3.2.5. By Route of Administration
        • 9.4.3.2.6. By End-User

10. Middle East and Africa Nuclear Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Type
    • 10.2.3. By Application
    • 10.2.4. By Therapeutics
    • 10.2.5. By Route of Administration
    • 10.2.6. By End-User
    • 10.2.7. By Country
  • 10.3. Market Attractiveness Index
  • 10.4. MEA: Country Analysis
    • 10.4.1. South Africa Nuclear Medicine Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Therapy
        • 10.4.1.2.2. By Type
        • 10.4.1.2.3. By Application
        • 10.4.1.2.4. By Therapeutics
        • 10.4.1.2.5. By Route of Administration
        • 10.4.1.2.6. By End-User
    • 10.4.2. Saudi Arabia Nuclear Medicine Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Therapy
        • 10.4.2.2.2. By Type
        • 10.4.2.2.3. By Application
        • 10.4.2.2.4. By Therapeutics
        • 10.4.2.2.5. By Route of Administration
        • 10.4.2.2.6. By End-User
    • 10.4.3. UAE Nuclear Medicine Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Therapy
        • 10.4.3.2.2. By Type
        • 10.4.3.2.3. By Application
        • 10.4.3.2.4. By Therapeutics
        • 10.4.3.2.5. By Route of Administration
        • 10.4.3.2.6. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Competition Outlook
  • 13.2. Players Profiled (Leading Companies)
    • 13.2.1. Cardinal Health
    • 13.2.2. Curium
    • 13.2.3. Lantheus
    • 13.2.4. Bracco
    • 13.2.5. Advanced Accelerator Applications
    • 13.2.6. NTP Radioisotopes
    • 13.2.7. Eckert & Ziegler
    • 13.2.8. Jubilant DraxImage
    • 13.2.9. GE Healthcare
    • 13.2.10. Siemens Healthineers
    • 13.2.11. Rotem Industries
    • 13.2.12. Eczacibasi-Monrol
    • 13.2.13. IBA Group
    • 13.2.14. Ire-Elit
    • 13.2.15. Lucerno Dynamics
    • 13.2.16. Positron Corporation
    • 13.2.17. NorthStar Medical Radioisotopes
    • 13.2.18. Pharmalucence
    • 13.2.19. Norgine
    • 13.2.20. Roche

14. Strategic Recommendations

15. About Us & Disclaimer

Back to Top
전화 문의
F A Q